Skip to content

Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage

Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03602677
Acronym
ICG-COLORAL
Enrollment
1062
Registered
2018-07-27
Start date
2018-09-24
Completion date
2023-12-01
Last updated
2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Colorectal Neoplasms, Diverticulosis, Colonic, Gastrointestinal Cancer, Gastrointestinal Disease, Gastrointestinal Neoplasms

Keywords

Colorectal surgery, Anastomosis, Anastomosis leak, Fluorescence imaging

Brief summary

This is a randomized, controlled, parallel, multicenter trial to determine the difference in post-operative anastomotic leakages in colorectal surgery, where anastomosis perfusion is evaluated using indocyanine green fluorescence imaging as an addition to standard surgical practice compared to surgical practice alone.

Interventions

DEVICEICG fluorescence imaging

The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.

Sponsors

University of Oulu
CollaboratorOTHER
Central Finland Hospital District
CollaboratorOTHER
Tampere University Hospital
CollaboratorOTHER
Turku University Hospital
CollaboratorOTHER_GOV
Hospital District of Helsinki and Uusimaa
CollaboratorOTHER
Päijänne Tavastia Central Hospital
CollaboratorOTHER
Seinäjoki Central Hospital, Seinäjoki, Finland
CollaboratorUNKNOWN
Oulu University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All consenting patients in the catchment area of participating hospitals who undergo elective colorectal surgery with planned primary anastomosis are eligible for this study. * Of rectal cancer patients only those with pathology in the proximal third will be included in the study (defined by area proximal from peritoneal fold).

Exclusion criteria

* Emergent patients * Patients with proven diverticular abscess and colonic fistulas are excluded * Patients with planned open surgery are excluded.

Design outcomes

Primary

MeasureTime frame
Anastomosis leakage rate0 to 90 days

Secondary

MeasureTime frameDescription
30- and 90-day mortality0 to 90 days
Reoperation rate0 to 90 days
30- and 90-day complications according to Clavien-Dindo Classification0 to 90 daysClavien-Dindo Score from Grade 0 (no complications) to Grade V (Death of a patient). Five grades and additionally Grade III and IV will be divided to a and b.
Operation time0-600 minutesTime from the start of the operation until the surgeon has ended the operation
Severity of anastomosis leakage0 to 90 daysGrade A-C according to International Study Group of Rectal Cancer
Length of hospital stay0-365 daysDay of the operation is considered the day 0
Deep surgical site infections0 to 90 daysYes/no
Hospital readmission rate0 to 90 days
Time to first bowel movement0-30 daysPostoperative day when the first bowel movement occurs
Time to first flatus0-30 daysPostoperative day when the first flatus occurs
Hospital costs0 to 90 days
Timing of anastomosis leakage0 to 90 daysDays

Countries

Finland

Contacts

Primary ContactJyrki Kössi, MD, PhD
jyrki.kossi@phhyky.fi+358381911
Backup ContactOlli Helminen, MD, PhD
olli.helminen@oulu.fi+358142691811

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026